Peutz–Jeghers syndrome and screening for pancreatic cancer
Article first published online: 17 NOV 2006
Copyright © 2006 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
British Journal of Surgery
Volume 93, Issue 12, pages 1446–1455, December 2006
How to Cite
Latchford, A., Greenhalf, W., Vitone, L. J., Neoptolemos, J. P., Lancaster, G. A. and Phillips, R. K. S. (2006), Peutz–Jeghers syndrome and screening for pancreatic cancer. Br J Surg, 93: 1446–1455. doi: 10.1002/bjs.5609
- Issue published online: 17 NOV 2006
- Article first published online: 17 NOV 2006
- Manuscript Accepted: 10 AUG 2006
- European Union (Framework 5), North West Cancer Research Fund, North West Region Biomed, Cancer Research UK, Frances and Augustus Newman Foundation, Royal Liverpool University Hospital R&D Department, Solvay Healthcare, Hanover and Medical Research Council Co-operative grants
Cancer risk, including pancreatic, is high in those with Peutz–Jeghers syndrome (PJS). It has been suggested that such patients should undergo screening for pancreatic cancer.
The risk of pancreatic cancer in PJS, pancreatic screening and potential screening strategies were reviewed. Cost-effectiveness was assessed according to American Gastroenterology Association guidelines and a risk stratification model proposed by the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer.
The risk of pancreatic cancer is increased in PJS but screening would cost over US $350 000 per life saved. Risk stratification reduces cost by $100 000 and costs fall to $50 000 per life saved if deaths from other forms of cancer are avoided.
Screening should be performed only on a research basis to evaluate the benefit and cost-effectiveness in high-risk groups. Copyright © 2006 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.